Education

Biography

Srinivas Nandana, Ph.D., is an Assistant Professor in the Dept. of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock. Dr. Nandana received his Ph.D. from the laboratory of Dr. Robert Matusik at Vanderbilt University, Nashville, where he worked on creating a transgenic mouse model of Prostate Cancer progression. Subsequently he pursued his Post-Doctoral training in the laboratory of Dr. Leland Chung at Cedars-Sinai Medical Center, Los Angeles, and his research focused on the molecular mechanisms that drive Prostate Cancer bone metastasis. Dr. Nandana’s research focuses on creating and using mouse models to study the signaling and immune mechanisms that mediate Prostate Cancer metastasis.

Research Interest

Signaling mechanisms that orchestrate Prostate Cancer bone metastasis, Development of Mouse Models to closely mimic Prostate Cancer metastatic progression, Chemokine Signaling in Prostate Cancer homing to the bone, Role of the immune microenvironment in Prostate Cancer bone metastasis

Scientific Activities

Awards and Honors

• 2007: AACR Travel Award to attend the Edward A. Smuckler Memorial Pathobiology of Cancer Workshop
• 2006: Travel Award, Society for Basic Urologic Research
• 2002: Fellowship, Interdisciplinary Graduate Program (IGP) in Biomedical Sciences, Vanderbilt University
• 2000: Dissertation Research Scholarship, Barkatullah University

Memberships

• Associate Member, American Association for Cancer Research
• Member, Society for Basic Urologic Research
• Member, Cancer and Bone Society

Publications

1. Chu C.Y., Chung L.W.K, Gururajan M., Hsieh C.L., Josson S., Nandana S., Sung S.Y., Wang R., Wu J.B., Zhau H.E. Regulatory Signaling Network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics. Asian Journal of Urology (In Press)
2. Tripathi M. *, Nandana S. *, Billet S., Cavassani K., Chung L.W.K., Posadas E.M., Bhowmick N.A. Modulation of cabozantinib efficacy by the prostate tumor microenvironment. 2017; Sep 23; 8(50): 87891-87902 (*contributed equally)
3. Nandana S.*, Tripathi M.*, Duan P., Chu C.Y., Mishra R., Liu C., Jin R., Yamashita H., Zayzafoon M., Bhowmick N.A., Zhau H.E., Matusik R.J. and Chung L.W.K.# Bone metastasis of prostate cancer can be therapeutically targeted at the TBX2-WNT signaling axis. Cancer Research, 2017; Mar 15; 77(6):1331-1344 (*contributed equally, # denotes co-corresponding authorship)
4. Gururajan M., Cavassani K.A., Sievert M., Duan P., Lichterman J., Huang J.M., Smith B., You S., Nandana S., Chu G.C., Mink S., Josson S., Liu C., Morello M., Jones L.W., Kim J., Freeman M.R., Bhowmick N., Zhau H.E., Chung L.W., Posadas E.M. SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer. Oncotarget, 2015 Nov 26, Vol 6, No 42: 44072-83
5. Josson S., Gururajan M., Hu P., Shao C., Chu G.Y., Zhau H.E., Liu C., Lao K., Lu C.L., Lu Y.T., Lichterman J., Nandana S., Li Q., Rogatko A., Berel D., Posadas E.M., Fazli L., Sareen D., Chung L.W. miR-409-3p/5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of prostate cancer. Clinical Cancer Res, 2014 Sep 1; 20(17): 4636-46
6. Nandana S. and Chung L.W.K. Prostate Cancer Progression and Metastasis: Current and Potential Therapeutic Pathways & Mouse Models in Pre-Clinical Research. American Journal of Clinical and Experimental Urology, 2014 Jul 12; 2(2): 92-101
7. Nandana S., Ellwood-Yen K., Sawyers C.L., Wills M.L., Weidow B., Case T.C., Vasioukhin V., and Matusik R.J. Hepsin co-operates with myc in the progression of adenocarcinoma in a prostate cancer mouse model. Prostate, 2010 May, 70(6):591-600
8. Degraff D.J., Yu X., Sun Q., Mirosevich J., Jin R.J., Wang Y., Gupta A., Nandana S., Case T., Paul M., Huang H.Y., Shapiro E., Logan S., Suzuki K., Orgebin-Crist M.C., Matusik R.J. The role of Foxa proteins in the regulation of androgen receptor activity, Chapter 18, 587-615, 2009 Androgen Action in Prostate Cancer, Tindall D.J. and Mohler J.
9. Yi Y., Nandana S., Case T.C., Nelson C., Radmilovic T., Matusik R.J., Tsuchiya K.D. Candidate metastasis suppressor genes uncovered by array comparative genomic hybridization in a mouse allograft model of Prostate Cancer. Molecular Cytogenetics, 2009 Sep, 2:18
10. Tripathi M., Nandana S., Yamashita H., Kirchhofer D. and Quaranta V. Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression. Journal of Biological Chemistry, 2008 Nov, 283 (45):30576-84
11. Matusik R.J., Jin R.J., Sun Q., Wang Y., Yu X., Gupta A., Nandana S., Case T.C., Paul M., Mirosevich J., Oottamasathien S., Thomas J. Prostate epithelial cell fate. Differentiation, 2008 Jul, 76:(6) 682-98
12. Levititin F., Weiss M., Hahn Y., Stern O., Papke R.L., Matusik R.J., Nandana S., Ziv R, Pichinuk E., Salame S., Bera T, Vincent J, Lee B., Pastan I, and Wreschner D.H. PATE Gene Clusters Code for Multiple, Secreted TFP/Ly-6/uPAR Proteins that are expressed in reproductive and neuron-rich tissues and possess neuromodulatory activity. Journal of Biological Chemistry. 2008 Jun, 283(24):16928-16939
13. Kenchappa P., Yadav A., Singh G., Nandana S., Banerjee K. Rescue of TNF alpha inhibited neuronal cells by IGF-1 involves Akt and c-Jun N-terminal kinases. Journal of Neuroscience Research. Mar 2004, 76(4) 466-474

Abstracts

14. Tripathi M., Nandana S., Billet S. Posadas E.M., Chung LW.K. Microenvironment mediates the efficacy of cabozantinib in prostate cancer. Annual Research Day, Cedars-Sinai Medical Center, Feb 2016, Los Angeles, CA.
15. Tripathi M., Nandana S., Huang J., Kato M., Chung L.W.K., Xin L., Bhowmick N.A. Reciprocal prostate cancer signaling with its microenvironment mediates castrate resistant disease progression. AACR Special Conference – The function of Tumor Microenvironment in Cancer Progression, Jan 2016, San Diego, CA
16. Nandana S., Tripathi M., Duan P., Chu C., Mishra R., Liu C., Jin R., Yamashita H., Zayzafoon M., Bhowmick N.A., Zhau H.E., Matusik R.J. and Chung L.W.K. TBX2-WNT signaling axis – a new therapeutic target for prostate cancer bone metastasis. The Stem Cell Niche and Cancer Microenvironment Symposium, Cedars-Sinai Medical Center, Nov 2015, Los Angeles, CA
17. Tripathi M., Nandana S., Billet S., Posadas E.M., Chung L.W.K. Microenvironment mediates the efficacy of cabozantinib in prostate cancer. The Stem Cell Niche and Cancer Microenvironment Symposium, Cedars-Sinai Medical Center, Nov 2015, Los Angeles, CA
18. Nandana S., Tripathi M., Chu C., Bhowmick N.A., Matusik R.J. and Chung L.W.K. Blocking endogenous TBX2 expression in PC3 prostate cancer cells abrogates bone metastasis in a xenograft mouse model. AACR Special Conference on Tumor Invasion and Metastasis, Jan 2013, San Diego, CA
19. Nandana S., Tripathi M., Chu C., Matusik R.J. and Chung L.W.K. Blocking TBX2 abrogates bone metastasis in a xenograft mouse model of prostate cancer. Fourth Annual Cancer Institute Research Poster Presentation, Cedars-Sinai Medical Center, June 2012, Los Angeles, CA
20. Nandana S., Jin R., Yamashita H., Shao C., Matusik R.J. and Chung LW.K. TBX2, a senescence-related transcription factor mediates its action through BMP2 and RANKL contributing to prostate cancer growth and bone metastasis. 11th International Conference on Cancer-Induced Bone Disease, Dec 2011, Chicago, IL
21. Nandana S., Matusik R.J. Blocking endogenous TBX2 in PC3 human prostate cancer cells reduces in vivo invasion, metastasis and growth in bone microenvironment. Department of Defense Prostate Cancer IMPACT Meeting, March 2011, Orlando, Florida
22. Yamashita H., Tripathi M., Nandana S., Ganesan R., Kirchhofer D. and Quaranta V. Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression. Hormones and Cancer. Volume 2, Issue 1, pp 3-37. Sixth International Symposium on Hormonal Oncogenesis, Sheraton Grande Tokyo Bay Hotel, Feb 2011, Tokyo, Japan
23. Tripathi M., Nandana S., Yamashita H., Kirchhofer D. and Quaranta V. Cleavage of Laminin-332 by hepsin and its implications in the progression of prostate cancer. Vanderbilt-Ingram Cancer Center Retreat, Student Life Center Vanderbilt University, May 2009, Nashville, TN
24. Yu X.*, Nandana S.*, Saliganan A., Case T.C., Paul M., Kim H., Fridman R., Bonfil D.R., Cher M. and Matusik R.J. (*contributed equally) The Role of MT1-MMP and PDGF-D in Prostate Cancer Progression. AACR Special Conference, Advances in Prostate Cancer Research, Jan 2009, San Diego, CA
25. Nandana S. and Matusik R.J. TBX2 mediates osteogenic burden of PC3 human prostate cancer cells in the bone microenvironment. SBUR Fall Annual Meeting, Nov 2008, Phoenix, Arizona
26. Nandana S., Chevillet J., Ellwood-Yen K., Sawyers C.L., Wills M.L., Case T.C., Vasioukhin V., and Matusik R.J. Hepsin co-operates with myc in the progression of adenocarcinoma in a Prostate Cancer mouse model. AACR Edward A. Smuckler Memorial Workshop in Pathobiology of Cancer, Aug 2007, Snowmass, Colorado
27. Nandana S., Chevillet J., Ellwood-Yen K., Sawyers C.L., Wills M.L., Case T.C., Vasioukhin V., and Matusik R.J. Investigation of the hepsin/myc mouse model in the progression of prostate cancer. SBUR Fall Annual Meeting, Nov 2006, Phoenix, Arizona
28. Nandana S. and Matusik R.J. Investigation of the role of TBX2 in androgen regulation and prostate cancer progression. Vanderbilt University Department of Cancer Biology Annual Retreat, Nov 2005, Lake Barkley State Resort Park, Cadiz, Kentucky